Bioprexum Plus Contraindications

Linked to perindopril: Hypersensitivity to the active substance or to any other ACE inhibitor.
History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy (see "Precautions").
Hereditary/idiopathic angioedema.
Second and third trimesters of pregnancy (see "Precautions", "Use in Pregnancy & Lactation").
Concomitant use of BIOPREXUM Plus 5 mg/1.25 mg with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²) (see "Interactions" and "Pharmacology: Pharmacodynamics under Actions").
Concomitant use with sacubitril/valsartan therapy. BIOPREXUM Plus 5 mg/1.25 mg must not be initiated earlier than 36 hours after the last dose of sacubitril/valsartan (see "Precautions" and "Interactions").
Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see "Interactions").
Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see "Precautions").
Linked to indapamide: Hypersensitivity to the active substance or to any other sulphonamides.
Severe renal impairment (creatinine clearance below 30 mL/min).
Hepatic encephalopathy.
Severe hepatic impairment.
Hypokalaemia.
Linked to BIOPREXUM Plus 5 mg/1.25 mg: Hypersensitivity to any of the excipients.
Due to the lack of sufficient therapeutic experience, BIOPREXUM Plus 5 mg/1.25 mg should not be used in: Dialysis patients; Patients with untreated decompensated heart failure.